NCT00250887

A Phase II Open Label Study of the Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research

Completed Phase 2 Last updated 22 October 2007

What this trial tests

Phase 2 trial testing Gefitnib in Recurrent Glioblastoma in 22 participants. Completed in 1 May 2007.

Timeline

1 July 2005

1 May 2007

Quick facts

Lead sponsor	University of Zurich
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	1 July 2005
Estimated completion	1 May 2007
Sites	1 location across Switzerland

Drugs / interventions tested

• Gefitnib — full drug profile →

Conditions studied

• Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →

Sponsor

University of Zurich

Who can join

18 and older, any sex, with Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• molecular signature of EGFR responsiveness to ZD1839

Sponsor's own description

This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy). Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR). EGFR is elevated in more than 50% of malignant gliomas. At recurrence, secondary surgery and pre- and postoperative Gefitinib is offered to patients in good performance status. Clinical outcome of patients and correlation to translational research will be evaluated.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
   Li X, Wu C, Chen N, Gu H, et al · · 2016 · cited 406× · PMID 26967052 · DOI 10.18632/oncotarget.7961
2. Glioblastoma Therapy: Past, Present and Future.
   Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, et al · · 2024 · cited 147× · PMID 38473776 · DOI 10.3390/ijms25052529
3. Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update.
   Colardo M, Segatto M, Di Bartolomeo S. · · 2021 · cited 102× · PMID 34063168 · DOI 10.3390/ijms22094899
4. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
   Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, et al · · 2021 · cited 99× · PMID 33918704 · DOI 10.3390/cancers13081795
5. Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies.
   Kang H, Lee H, Kim D, Kim B, et al · · 2022 · cited 30× · PMID 35740330 · DOI 10.3390/biomedicines10061308
6. Molecular targeted therapy: A new avenue in glioblastoma treatment.
   El Atat O, Naser R, Abdelkhalek M, Habib RA, et al · · 2023 · cited 24× · PMID 36644133 · DOI 10.3892/ol.2022.13632
7. Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
   Aldaz P, Arozarena I. · · 2021 · cited 24× · PMID 34830952 · DOI 10.3390/cancers13225799
8. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
   Stitzlein LM, Adams JT, Stitzlein EN, Dudley RW, et al · · 2024 · cited 22× · PMID 38183103 · DOI 10.1186/s13046-023-02923-7